<p>StockNews.com 的投資分析師在週一發佈給投資者的研究報告中開始覆蓋藍鳥生物（NASDAQ:BLUE - 獲取免費報告）的股票。該經紀公司對這家生物技術公司的股票給予了 “賣出” 評級。</p>
<ul>
<li>Beam Therapeutics 因基因治療許可支付而大幅上漲</li>
</ul>
<p>其他幾位研究分析師最近也對 BLUE 發表了看法。巴克萊將藍鳥生物的目標價從 4.00 美元下調至 2.00 美元，並在週五的研究報告中對該公司給予了 “增持” 評級。羅伯特·W·貝爾德將藍鳥生物的目標價從 7.00 美元下調至 6.00 美元，並在 8 月 15 日的研究報告中對該股票給予了 “跑贏大盤” 評級。美國銀行將藍鳥生物的股票評級從 “買入” 下調至 “中性”，並在週五的研究報告中將該公司的目標價從 3.00 美元下調至 0.50 美元。Cantor Fitzgerald 在 9 月 16 日的報告中重申了對藍鳥生物股票的 “中性” 評級。最後，摩根大通在週五的研究報告中將藍鳥生物的股票評級從 “中性” 下調至 “減持”。三位股票研究分析師對該股票給予了賣出評級，七位給予了持有評級，兩位給予了買入評級。根據 MarketBeat 的數據，該股票目前的共識評級為 “持有”，平均目標價為 3.03 美元。</p>
<p><strong>查看我們對藍鳥生物的最新分析</strong></p>
<h2>藍鳥生物股價下跌 11.5%</h2>
<ul>
<li>MarketBeat 週迴顧 – 2/26 - 3/1</li>
</ul>
<p>週一，BLUE 股票開盤價為 0.32 美元。該股票的市值為 6221 萬美元，市盈率為 -0.17，貝塔值為 0.76。該公司的速動比率為 0.57，流動比率為 0.68，債務與股本比率為 0.37。藍鳥生物的 52 周低點為 0.32 美元，52 周高點為 5.53 美元。該公司的 50 日簡單移動平均線為 0.49 美元，200 日簡單移動平均線為 0.78 美元。</p>
<p>藍鳥生物（NASDAQ:BLUE - 獲取免費報告）最近一次發佈財報是在 9 月 13 日，生物技術公司報告該季度每股收益為 -0.36 美元。該季度的收入為 1857 萬美元。藍鳥生物的淨利潤率為 -565.74%，股本回報率為 -238.15%。分析師平均預測藍鳥生物在當前財年將發佈 -1.41 美元的每股收益。</p>
<h2>機構資金流入和流出</h2>
<ul>
<li>藍鳥生物股票顯示出成為多倍收益股的潛力</li>
</ul>
<p>一些機構投資者最近對 BLUE 的持倉進行了調整。阿勒格尼金融集團在第二季度購買了藍鳥生物的新頭寸，價值 25,000 美元。Verition 基金管理公司在第三季度收購了藍鳥生物的股份，價值約 42,000 美元。貝葉斯資本管理公司在第一季度購買了藍鳥生物的新頭寸，價值約 52,000 美元。SG 美洲證券公司在第三季度將其在藍鳥生物的持股增加了 152.4%。SG 美洲證券公司現在擁有 122,855 股該生物技術公司的股票，價值 64,000 美元，此前在上個季度購買了額外的 74,185 股。最後，Price T Rowe Associates Inc. MD 在第一季度將其在藍鳥生物的持倉增加了 113.7%。Price T Rowe Associates Inc. MD 現在擁有 54,714 股該生物技術公司的股票，價值 71,000 美元，此前在上個季度購買了額外的 29,113 股。87.43% 的股票由機構投資者持有。</p>
<h2>藍鳥生物公司簡介</h2>
<p>(獲取免費報告)</p>
<p>藍鳥生物公司是一家生物技術公司，研究、開發和商業化用於治療嚴重遺傳疾病的基因療法。其針對嚴重遺傳疾病的產品候選包括 ZYNTEGLO（betibeglogene autotemcel）用於治療輸血依賴性β-地中海貧血；lovotibeglogene autotemcel 用於治療鐮狀細胞病（SCD）；以及 SKYSONA（elivaldogene autotemcel）用於治療腦性腎上腺白質營養不良症。</p>
<h2>另請參閲</h2>
<ul>
<li>我們更看好的五隻股票，勝過藍鳥生物</li>
<li>電動車股票及其獲利方式</li>
<li>沃倫·巴菲特、凱西·伍德持有 Nu Holdings，你應該買嗎？</li>
<li>美股下跌 23% 後：是否是買入的好時機？</li>
<li>納斯達克是什麼？完整概述及歷史</li>
<li>ORIC：與兩家制藥巨頭合作，分析師預計有 +100% 的上漲空間</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QkxVRQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QkxVRQ"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前經過 MarketBeat 編輯團隊的審查。如對本故事有任何問題或意見，請發送電子郵件至 contact@marketbeat.com。</em></p>
<p>→ ❗ 請回復確認！ (來自市場背後)(廣告)</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMDU0Mw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMDU0Mw"/></p>
<h2>你現在應該投資 1,000 美元在藍鳥生物嗎？</h2>
<p>在你考慮藍鳥生物之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而藍鳥生物並不在名單上。</p>
<p>雖然藍鳥生物目前在分析師中獲得了 “持有” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

藍鳥生物

<p>StockNews.com 已經開始對藍鳥生物（NASDAQ:BLUE）進行覆蓋，給予其 “賣出” 評級。其他分析師也調整了他們的評級，巴克萊設定了 “增持” 評級，而美國銀行則將其下調至 “中性”。目前，該股票的共識評級為 “持有”，平均目標價為 3.03 美元。藍鳥生物報告了 565.74% 的負淨利潤率，預計本財年每股收益為 -1.41 美元。機構投資者持有該股票的 87.43%</p>

<p>Investment analysts at StockNews.com assumed coverage on shares of bluebird bio (NASDAQ:BLUE - Get Free Report) in a research note issued to investors on Monday. The brokerage set a &#34;sell&#34; rating on the biotechnology company's stock.</p>
<div class="lb-trans"><p>StockNews.com 的投資分析師在週一發佈給投資者的研究報告中開始覆蓋藍鳥生物（NASDAQ:BLUE - 獲取免費報告）的股票。該經紀公司對這家生物技術公司的股票給予了 “賣出” 評級。</p>
</div><ul>
<li>Beam Therapeutics Bolts Higher on Gene Therapy Licensing Payments</li>
</ul>
<div class="lb-trans"><ul>
<li>Beam Therapeutics 因基因治療許可支付而大幅上漲</li>
</ul>
</div><p>Several other research analysts also recently weighed in on BLUE. Barclays cut their target price on shares of bluebird bio from $4.00 to $2.00 and set an &#34;overweight&#34; rating for the company in a research note on Friday. Robert W. Baird cut their price objective on bluebird bio from $7.00 to $6.00 and set an &#34;outperform&#34; rating on the stock in a research report on Thursday, August 15th. Bank of America downgraded shares of bluebird bio from a &#34;buy&#34; rating to a &#34;neutral&#34; rating and decreased their target price for the company from $3.00 to $0.50 in a research note on Friday. Cantor Fitzgerald restated a &#34;neutral&#34; rating on shares of bluebird bio in a report on Monday, September 16th. Finally, JPMorgan Chase &amp; Co. cut shares of bluebird bio from a &#34;neutral&#34; rating to an &#34;underweight&#34; rating in a research report on Friday. Three equities research analysts have rated the stock with a sell rating, seven have given a hold rating and two have issued a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of &#34;Hold&#34; and an average price target of $3.03.</p>
<div class="lb-trans"><p>其他幾位研究分析師最近也對 BLUE 發表了看法。巴克萊將藍鳥生物的目標價從 4.00 美元下調至 2.00 美元，並在週五的研究報告中對該公司給予了 “增持” 評級。羅伯特·W·貝爾德將藍鳥生物的目標價從 7.00 美元下調至 6.00 美元，並在 8 月 15 日的研究報告中對該股票給予了 “跑贏大盤” 評級。美國銀行將藍鳥生物的股票評級從 “買入” 下調至 “中性”，並在週五的研究報告中將該公司的目標價從 3.00 美元下調至 0.50 美元。Cantor Fitzgerald 在 9 月 16 日的報告中重申了對藍鳥生物股票的 “中性” 評級。最後，摩根大通在週五的研究報告中將藍鳥生物的股票評級從 “中性” 下調至 “減持”。三位股票研究分析師對該股票給予了賣出評級，七位給予了持有評級，兩位給予了買入評級。根據 MarketBeat 的數據，該股票目前的共識評級為 “持有”，平均目標價為 3.03 美元。</p>
</div><p><strong>View Our Latest Analysis on bluebird bio</strong></p>
<div class="lb-trans"><p><strong>查看我們對藍鳥生物的最新分析</strong></p>
</div><h2>bluebird bio Trading Down 11.5 %</h2>
<div class="lb-trans"><h2>藍鳥生物股價下跌 11.5%</h2>
</div><ul>
<li>MarketBeat Week in Review – 2/26 - 3/1</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 週迴顧 – 2/26 - 3/1</li>
</ul>
</div><p>Shares of BLUE stock opened at $0.32 on Monday. The stock has a market cap of $62.21 million, a P/E ratio of -0.17 and a beta of 0.76. The company has a quick ratio of 0.57, a current ratio of 0.68 and a debt-to-equity ratio of 0.37. bluebird bio has a fifty-two week low of $0.32 and a fifty-two week high of $5.53. The business has a fifty day simple moving average of $0.49 and a 200-day simple moving average of $0.78.</p>
<div class="lb-trans"><p>週一，BLUE 股票開盤價為 0.32 美元。該股票的市值為 6221 萬美元，市盈率為 -0.17，貝塔值為 0.76。該公司的速動比率為 0.57，流動比率為 0.68，債務與股本比率為 0.37。藍鳥生物的 52 周低點為 0.32 美元，52 周高點為 5.53 美元。該公司的 50 日簡單移動平均線為 0.49 美元，200 日簡單移動平均線為 0.78 美元。</p>
</div><p>bluebird bio (NASDAQ:BLUE - Get Free Report) last posted its earnings results on Friday, September 13th. The biotechnology company reported ($0.36) earnings per share for the quarter. The business had revenue of $18.57 million for the quarter. bluebird bio had a negative net margin of 565.74% and a negative return on equity of 238.15%. On average, analysts forecast that bluebird bio will post -1.41 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>藍鳥生物（NASDAQ:BLUE - 獲取免費報告）最近一次發佈財報是在 9 月 13 日，生物技術公司報告該季度每股收益為 -0.36 美元。該季度的收入為 1857 萬美元。藍鳥生物的淨利潤率為 -565.74%，股本回報率為 -238.15%。分析師平均預測藍鳥生物在當前財年將發佈 -1.41 美元的每股收益。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>機構資金流入和流出</h2>
</div><ul>
<li>bluebird bio Stock Signals Potential to be a Multi-bagger</li>
</ul>
<div class="lb-trans"><ul>
<li>藍鳥生物股票顯示出成為多倍收益股的潛力</li>
</ul>
</div><p>A number of institutional investors have recently made changes to their positions in BLUE. Allegheny Financial Group LTD bought a new position in bluebird bio during the second quarter worth $25,000. Verition Fund Management LLC acquired a new stake in shares of bluebird bio during the 3rd quarter worth about $42,000. Bayesian Capital Management LP bought a new position in bluebird bio during the 1st quarter valued at about $52,000. SG Americas Securities LLC boosted its stake in bluebird bio by 152.4% in the third quarter. SG Americas Securities LLC now owns 122,855 shares of the biotechnology company's stock worth $64,000 after purchasing an additional 74,185 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its position in shares of bluebird bio by 113.7% during the first quarter. Price T Rowe Associates Inc. MD now owns 54,714 shares of the biotechnology company's stock worth $71,000 after purchasing an additional 29,113 shares in the last quarter. 87.43% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>一些機構投資者最近對 BLUE 的持倉進行了調整。阿勒格尼金融集團在第二季度購買了藍鳥生物的新頭寸，價值 25,000 美元。Verition 基金管理公司在第三季度收購了藍鳥生物的股份，價值約 42,000 美元。貝葉斯資本管理公司在第一季度購買了藍鳥生物的新頭寸，價值約 52,000 美元。SG 美洲證券公司在第三季度將其在藍鳥生物的持股增加了 152.4%。SG 美洲證券公司現在擁有 122,855 股該生物技術公司的股票，價值 64,000 美元，此前在上個季度購買了額外的 74,185 股。最後，Price T Rowe Associates Inc. MD 在第一季度將其在藍鳥生物的持倉增加了 113.7%。Price T Rowe Associates Inc. MD 現在擁有 54,714 股該生物技術公司的股票，價值 71,000 美元，此前在上個季度購買了額外的 29,113 股。87.43% 的股票由機構投資者持有。</p>
</div><h2>bluebird bio Company Profile</h2>
<div class="lb-trans"><h2>藍鳥生物公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(獲取免費報告)</p>
</div><p>bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.</p>
<div class="lb-trans"><p>藍鳥生物公司是一家生物技術公司，研究、開發和商業化用於治療嚴重遺傳疾病的基因療法。其針對嚴重遺傳疾病的產品候選包括 ZYNTEGLO（betibeglogene autotemcel）用於治療輸血依賴性β-地中海貧血；lovotibeglogene autotemcel 用於治療鐮狀細胞病（SCD）；以及 SKYSONA（elivaldogene autotemcel）用於治療腦性腎上腺白質營養不良症。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另請參閲</h2>
</div><ul>
<li>Five stocks we like better than bluebird bio</li>
<li>EV Stocks and How to Profit from Them</li>
<li>Warren Buffett, Cathie Wood Own Nu Holdings, Should You?</li>
<li>Are Penny Stocks a Good Fit for Your Portfolio?</li>
<li>MercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?</li>
<li>What is the Nasdaq? Complete Overview with History</li>
<li>ORIC: Working with Two Pharma Giants, Analysts See +100% Upside</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，勝過藍鳥生物</li>
<li>電動車股票及其獲利方式</li>
<li>沃倫·巴菲特、凱西·伍德持有 Nu Holdings，你應該買嗎？</li>
<li>美股下跌 23% 後：是否是買入的好時機？</li>
<li>納斯達克是什麼？完整概述及歷史</li>
<li>ORIC：與兩家制藥巨頭合作，分析師預計有 +100% 的上漲空間</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QkxVRQ" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=BLUE"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前經過 MarketBeat 編輯團隊的審查。如對本故事有任何問題或意見，請發送電子郵件至 contact@marketbeat.com。</em></p>
</div><p>→ ❗ RSVP please! (From Behind the Markets)(Ad)</p>
<div class="lb-trans"><p>→ ❗ 請回復確認！ (來自市場背後)(廣告)</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMDU0Mw" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=10543&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in bluebird bio right now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在藍鳥生物嗎？</h2>
</div><p>Before you consider bluebird bio, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮藍鳥生物之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and bluebird bio wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而藍鳥生物並不在名單上。</p>
</div><p>While bluebird bio currently has a &#34;Hold&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然藍鳥生物目前在分析師中獲得了 “持有” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

藍鳥生物（NASDAQ:BLUE）現已被 StockNews.com 覆蓋